

## Case report

### Hepatic primary neuroendocrine carcinoma: about a new case

Hasna Derouich<sup>1</sup>, Fouad Haddad<sup>1</sup>, Mohamed Moukhliissi<sup>1, &</sup>, Wafaa Hliwa<sup>1</sup>, Ahmed Bellabah<sup>1</sup>, Wafaa Badre<sup>1</sup>

<sup>1</sup>Gastroenterology, Oncology Departemnt Ibn Rochd Hospital, Casablanca, Morocco

<sup>&</sup>Corresponding author: Mohamed Moukhliissi, Gastroenterology, Oncology Departemnt Ibn Rochd Hospital, Casablanca, Morocco

Key words: Carcinoma, neuroendocrine, liver

Received: 03/11/2014 - Accepted: 03/03/2015 - Published: 17/03/2015

#### Abstract

We report a new case of Primary hepatic neuroendocrine carcinoma admitted in our hospital and revealed in 53 years man by epigastric pain and flush syndrome. A liver biopsy with immunohistochemical study confirmed the original location of a neuroendocrine carcinoma. After 12 cures of Chemotherapy and a follow up of 12 months, the patient is still in complete remission.

**Pan African Medical Journal. 2015; 20:254 doi:10.11604/pamj.2015.20.254.5710**

This article is available online at: <http://www.panafrican-med-journal.com/content/article/20/254/full/>

© Mohamed Moukhliissi et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Introduction

---

Endocrine tumors are characterized by a common phenotype general markers (i.e., neuron-specific enolase, chromogranin, synaptophysin) and hormonal secretion products. Primitive hepatic localization is very rare, representing less than 0.3% of all endocrine tumors of the digestive system with a female predominance; the sex ratio is 1.6 / 1, with an average age of 51 [1,2].

## Patient and observation

---

We report a case of primary hepatic neuroendocrine carcinoma (PHNEC) admitted in our department. A 53 years old patient, known diabetic, admitted for epigastric pain combined with diarrhea, abdominal distension and flush syndrome. This evolved in a deterioration of general condition. The clinical exam attested a facial reddening, hepatomegaly. An abdominal ultrasound showed a giant hepatic hemangioma of the posterior segment. A thoraco-abdominal-pelvic CT objective tumor lesion localized segment VI and VII of the liver with ascites (**Figure 1**).

Digestive endoscopy was performed for the patient and no Neoplasm was found in the stomach, duodenum, colon, or rectum. Capsule endoscopy for the small intestine was normal. Serum 5-HT, chromogranin A (CgA), and urinary 5-hydroxyindoleacetic acid (5-HIAA) examinations were very high with values of 225 ng/ml and 19 mg/24h successively. CT scan of the thorax was normal. The patient were Alpha Fetoprotein (AFP-), Carcinoembryonic antigen (CEA -) and Carcinoma Antigen (CA19-9-).

A liver biopsy with immunohistochemical study confirmed the diagnosis of primary neuroendocrine carcinoma (**Figure 2, Figure 3, Figure 4**). The patient has received chemotherapy with Cisplatin 100 mg/m<sup>2</sup>/day J1 and Etoposide 100 mg/m<sup>2</sup>/day J1 to J3 for 6 months, with good clinical and radiological improvement, and then he undergone 6 months more treatments: 12 months of treatments in total. After 18 months of follow up, the patient is in complete remission and we opted for a clinical and radiological monitoring.

## Discussion

---

Primary hepatic neuroendocrine carcinoma is rare [1,2], clinical symptoms are not specific, and imaging is fundamental to guide diagnosis. Serum 5-HT or hydroxyindoleacetic acid (5-HIAA) 24 h urine levels may be effective markers with sensitivity of 73% and a specificity of more than 90%. Serum (CGA) is a sensitive marker in the diagnosis with a sensitivity of 87-100% and a specificity of 92%, but diagnosis confirmation is the histological examination after biopsy or surgery [3].

It is difficult to differentiate PHNEC from other solid tumors, especially hepatocellular carcinoma or hepatic metastasis of other tumor; therefore, postoperative pathologic examination is the main method for a final diagnosis [1, 4]. Treatment includes several methods, surgery, systemic chemotherapy and transcatheter arterial chemoembolization [5,6]. Prognosis depends on the initial stage of the disease. Research indicated that the recurrence rate at 5 years was 18% and the survival rate at 5 years was 74% -78% [7].

## Conclusion

---

Primary hepatic neuroendocrine carcinoma remains a rare diagnosis, requiring careful biological, endoscopic, radiological and histological examinations to eliminate the secondary localization of extrahepatic tumor.

## Competing interests

---

The authors declare no competing interest.

## Authors' contributions

---

All authors read and agreed to the final version of this manuscript and equally contributed to its content and to the management of the case.

## Figures

---

**Figure 1:** CT scan image of a PHNEC patient; CT scan showing a liver mass (segment VI and VII)

**Figure 2:** microscopic image at low magnification showing tumor proliferation

**Figure 3:** hematoxylin eosin staining

**Figure 4:** immunohistochemistry, chromogranin A

## References


---

1. Yang-Qing Huang, Feng Xu, Jia-Mei Yang and Bin Huang. Primary hepatic neuroendocrine carcinoma: clinical analysis of 11 cases. *Hepatobiliary Pancreat Dis Int.* 2010; 9(1):44-48. **PubMed | Google Scholar**
2. Benameur A and al. Primary endocrine tumor of the lever : adifficult diagnosis. *J Afr Hepatol Gastroenterol.* 2012;6:103-106. **Google Scholar**


3. Ruo-Kun Li, Jing Zhao, Sheng-Xiang Rao, Cai-Zhong Chen, Meng-Su Zeng, Jin-Wei Qiang. Primary hepatic neuroendocrine carcinoma: MR imaging findings including preliminary observation on diffusion-weighted imaging. *Abdom Imaging.* 2013 Dec;38(6):1269-76. **PubMed | Google Scholar**
4. Bastaki W, Mothaffer F, Varro J, Al-Ghanim M, Malak L, Ayyash E, Asfar S. Primary hepatic carcinoid tumor. *Med Princ Pract.* 2005 Jul-Aug;14(4):288-91. **PubMed | Google Scholar**
5. Iwao M, Nakamuta M, Enjoji M, Kubo H, Fukutomi T, Tanabe Y et al. Primary hepatic carcinoid tumor: case report and review of 53 cases. *Med Sci Monit.* 2001 Jul-Aug;7(4):746-50. **PubMed | Google Scholar**
6. Bloomston M, Al-Saif O, Klemanski D, Pinzone JJ, Martin EW, Palmer B et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. *J Gastrointest Surg.* 2007 Mar;11(3):264-71. **PubMed | Google Scholar**
7. Knox CD, Anderson CD, Lamps LW, Adkins RB, Pinson CW. Long-term survival after resection for primary hepatic carcinoid tumor. *Ann Surg Oncol.* 2003 Dec;10(10):1171-5. **PubMed | Google Scholar**




**Figure 1:** CT scan image of a PHNEC patient; CT scan showing a liver mass (segment VI and VII)



**Figure 2:** microscopic image at low magnification showing tumor proliferation



**Figure 3:** hematoxylin eosin staining



**Figure 4:** immunohistochemistry, chromogranin A